Literature DB >> 22328001

CIP2A is a predictor of poor prognosis in colon cancer.

Hao-Wei Teng1, Shung-Haur Yang, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Jeng-Kai Jiang, Chueh-Chuan Yen, Anna Fen-Yau Li, Paul Chih-Hsueh Chen, Yuan-Tzu Lan, Chun-Chi Lin, Yen-Ning Hsu, Hsei-Wei Wang, Kuen-Feng Chen.   

Abstract

PURPOSE: The cancerous inhibitor of protein phosphatase 2A (CIP2A) oncoprotein is overexpressed in colon cancer tissue compared to normal colon mucosa. We investigated the impact of CIP2A on colon cancer.
METHODS: A tissue microarray consisting of 167 colon cancer specimens was investigated. The association between CIP2A and clinicopathological parameters was analyzed using the χ(2) test. Survival was analyzed using the Kaplan-Meier method. The impact of CIP2A on proliferation and drug resistance was evaluated using the 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide test. An anchorage-independent colony formation assay was also performed.
RESULTS: CIP2A was an independent prognostic factor in colon cancer after controlling for other clinical confounding factors, such as stage and lymphovascular invasion, particularly in stages III and IV (hazard ratio = 2.974, P < 0.001). The knockdown of CIP2A reduced the proliferation and anchorage-independent colony formation of colon cancer cells. Knockdown of CIP2A decreased the resistance of the cells to 5-fluorouracil, oxaliplatin, and SN38 (an active metabolite of irinotecan). Treatment with 5-fluorouracil, oxaliplatin, and SN38 decreased CIP2A expression.
CONCLUSIONS: CIP2A is a prognostic factor in colon cancer. The knockdown of CIP2A reduced proliferation and anchorage-independent colony formation and increased 5-fluorouracil, oxaliplatin, and SN38 efficacy in colon cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22328001     DOI: 10.1007/s11605-012-1828-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  24 in total

1.  State disparities in colorectal cancer mortality patterns in the United States.

Authors:  Deepa Naishadham; Iris Lansdorp-Vogelaar; Rebecca Siegel; Vilma Cokkinides; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07       Impact factor: 4.254

Review 2.  The MAPK signalling pathways and colorectal cancer.

Authors:  Jing Yuan Fang; Bruce C Richardson
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

3.  Regulation of Raf-1 activation and signalling by dephosphorylation.

Authors:  Amardeep S Dhillon; Sharon Meikle; Zihni Yazici; Manfred Eulitz; Walter Kolch
Journal:  EMBO J       Date:  2002-01-15       Impact factor: 11.598

4.  Single-cell multiplex gene detection and sequencing with microfluidically generated agarose emulsions.

Authors:  Richard Novak; Yong Zeng; Joe Shuga; Gautham Venugopalan; Daniel A Fletcher; Martyn T Smith; Richard A Mathies
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-10       Impact factor: 15.336

5.  Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Steven L Abrams; John T Lee; Fumin Chang; Fred E Bertrand; Patrick M Navolanic; David M Terrian; Richard A Franklin; Antonio B D'Assoro; Jeffrey L Salisbury; Maria Clorinda Mazzarino; Franca Stivala; Massimo Libra
Journal:  Adv Enzyme Regul       Date:  2006-07-18

6.  CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.

Authors:  Qian-Ze Dong; Yang Wang; Xin-Jun Dong; Zi-Xuan Li; Zhong-Ping Tang; Quan-Ze Cui; En-Hua Wang
Journal:  Ann Surg Oncol       Date:  2010-09-15       Impact factor: 5.344

Review 7.  A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.

Authors:  F Montagnani; A Chiriatti; G Turrisi; G Francini; G Fiorentini
Journal:  Colorectal Dis       Date:  2010-01-12       Impact factor: 3.788

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Authors:  Anchit Khanna; Camilla Böckelman; Annabrita Hemmes; Melissa R Junttila; Jan-Patrik Wiksten; Mikael Lundin; Siina Junnila; Daniel J Murphy; Gerard I Evan; Caj Haglund; Jukka Westermarck; Ari Ristimäki
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

Review 10.  Mechanisms of MYC stabilization in human malignancies.

Authors:  Melissa R Junttila; Jukka Westermarck
Journal:  Cell Cycle       Date:  2007-12-29       Impact factor: 4.534

View more
  30 in total

1.  Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Michelle Pusey; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-04-02

2.  Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.

Authors:  Vivi Ann Flørenes; Elisabeth Emilsen; Hiep Phuc Dong; Mette Førsund; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2015-02-07       Impact factor: 4.452

3.  Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.

Authors:  Xinxin Liu; Yurong Chai; Jitian Li; Pengfei Ren; Mei Liu; Liping Dai; Wei Qian; Wenjie Li; Jian-Ying Zhang
Journal:  Tumour Biol       Date:  2014-01-08

4.  CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.

Authors:  Mo Zhai; Lin Cong; Yaxin Han; Guanjun Tu
Journal:  Tumour Biol       Date:  2013-09-08

5.  CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.

Authors:  Yijun Xue; Gengqing Wu; Xiaoning Wang; Xiaofeng Zou; Guoxi Zhang; Rihai Xiao; Yuanhu Yuan; Dazhi Long; Jun Yang; Yuting Wu; Hui Xu; Folin Liu; Min Liu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

6.  Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Yong-Xian Cheng; Guang-Biao Zhou
Journal:  ACS Med Chem Lett       Date:  2013-12-20       Impact factor: 4.345

7.  Cancerous inhibitor of protein phosphatase 2A promotes premature chromosome segregation and aneuploidy in prostate cancer cells through association with shugoshin.

Authors:  Rajash Pallai; Aishwarya Bhaskar; Natalie Barnett-Bernodat; Christina Gallo-Ebert; Joseph T Nickels; Lyndi M Rice
Journal:  Tumour Biol       Date:  2015-03-04

8.  Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Authors:  Ae Lee Jeong; Sunyi Lee; Jeong Su Park; Sora Han; Chang-Young Jang; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

Review 9.  Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options.

Authors:  Godfrey Grech; Shawn Baldacchino; Christian Saliba; Maria Pia Grixti; Robert Gauci; Vanessa Petroni; Anthony G Fenech; Christian Scerri
Journal:  Tumour Biol       Date:  2016-07-21

10.  p90/CIP2A mediates breast cancer cell proliferation and apoptosis.

Authors:  Xinxin Liu; Bo Peng; Yang Li; Ningjing Lei; Wenjie Li; Jian-Ying Zhang
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.